DUBAI, UAE – September 10, 2026 — Xihong Biopharma successfully concluded its participation in Dubai Derma 2026, held from September 8–10 at the Dubai World Trade Centre. The exhibition provided an important platform for Xihong to present its regenerative aesthetic portfolio, engage with international industry stakeholders, and explore new opportunities for long-term market cooperation.
At Booth Z1G23, Zabeel Hall 1, Xihong welcomed distributors, physicians, clinic representatives, brand owners, and aesthetic professionals from a range of international markets. Discussions extended beyond individual products to encompass formulation, clinical applications, regulatory pathways, pricing structures, minimum order quantities, and market-specific distribution strategies.
Among the products presented, PLLA generated the strongest level of interest, followed by CaHA. Visitors showed particular interest in product specifications, applications, regulatory progress, and potential distribution models.
Xihong's PLLA products are currently undergoing CE registration, representing an important step in the company's international regulatory strategy. As the company continues to advance its global market development, Xihong is actively seeking qualified distributors and strategic partners worldwide for its PLLA portfolio.
Discussions with prospective partners frequently centered on CE registration timelines, MOQ requirements, and the potential for exclusive distribution arrangements. These conversations highlighted the growing interest in establishing long-term partnerships around Xihong's PLLA solutions.
While PLLA and CaHA remained the primary areas of interest, Xihong's Skin Booster portfolio received stronger-than-anticipated attention, particularly its PDRN and NCTF solutions.
Xihong's Skin Booster portfolio encompasses PDRN, NCTF, PLLA, and HA Skin Boosters, providing partners with access to multiple formulations and product concepts within a unified portfolio.
The breadth of the portfolio was particularly relevant to distributors and brand owners seeking to develop differentiated product offerings for their respective markets. Several visitors also took samples for further evaluation, with subsequent product discussions expected to continue following the exhibition.
A number of conversations initiated at Dubai Derma have already progressed toward the next stage of cooperation. Potential partners are preparing for online follow-up meetings, product evaluation, distribution discussions, and potential visits to Xihong's manufacturing facilities in China.
One prospective partner expressed particular interest in Xihong's manufacturing capabilities and plans to visit the company's production facilities to gain a closer understanding of its manufacturing processes and production lines.
The exhibition also reinforced interest in Xihong's broad product portfolio, competitive commercial positioning, and customization capabilities. Through its OEM and Private Label services, Xihong can work with international partners on product formulation, specifications, packaging, and brand customization according to market requirements.
Dubai Derma 2026 represents another step in Xihong Biopharma's ongoing international development. The company continues to expand its portfolio across PLLA, CaHA, PDRN, NCTF, HA, PCL, and other aesthetic injectable solutions, while advancing its regulatory strategy and strengthening relationships with international distributors and brand partners.
With growing interest in regenerative aesthetics and next-generation injectable solutions across global markets, Xihong remains focused on building sustainable, long-term partnerships grounded in product quality, manufacturing capabilities, and market-specific cooperation.
Xihong Biopharma is currently welcoming qualified distributors and strategic partners worldwide for its PLLA products, Skin Booster portfolio, regenerative aesthetic solutions, and OEM/Private Label cooperation.
